Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Nvidia is under pressure as traders debate the boards investigation into CEO Jensen Huang following reports of an affair with a woman suspected of ties to China, with some fearing national-security scrutiny or Huangs departure while others see the controversy as overblown. The community is split between continued selling and buying the dip ahead of earnings, with some also pointing to broader tech weakness.

A disappointing Q3 reportwith a surprise loss, squeezed margins, weaker-than-expected outlook and a sequential subscriber declinehas driven a sharp selloff. Traders are split between concerns about profitability and execution and hopes that international growth, the Lilly partnership and the planned Peptides+ launch can support a recovery.

Digital Turbines quarterly results triggered a sharp selloff despite revenue growth and a higher sales outlook, as gross-margin compression and unchanged profit guidance raised concerns about whether growth is translating into earnings. Traders are divided between viewing the drop as an overreaction and worrying that margin pressure and debt could weigh on the turnaround.

A third-quarter earnings beat, stronger-than-expected Q4 guidance, and an expanded buyback authorization sparked a sharp rally that quickly faded as traders weighed managements cautious tone and slowing underlying growth. Bulls see progress toward a turnaround, while skeptics point to declining year-over-year revenue, temporary revenue tailwinds, and doubts about management; the result has been intense debate over whether the report signals recovery or a sell-the-news move.

MARAs quarterly report has focused attention on its AI/HPC pivot: traders welcomed debt reduction, a share-repurchase authorization and an initial GPU-services contract, while noting that larger AI tenant leases remain unannounced. Reactions are split over whether the pivot can diversify the business, with skeptics emphasizing the revenue miss, Bitcoin-price exposure and execution risks.

PEPEs volatile rebounds and repeated tests of a key round-number resistance are drawing attention, with traders often pointing to relative strength when the broader crypto market weakens. Bulls see the bounces as signs of accumulation or a renewed meme-coin run, while skeptics warn the rallies may fade and emphasize the sharp pullbacks.

TG Therapeutics Q3 results and higher full-year revenue guidance, driven by continued BRIUMVI growth, are the main focus. Traders largely view the business update positively despite an initial selloff and sharp reversal; many are watching the upcoming subcutaneous BRIUMVI Phase 3 readout, while buyout and short-squeeze talk remains speculative.

Attention centers on the FDAs Nov. 22 decision on Capricors Deramiocel, with the current application emphasizing upper-limb function in Duchenne muscular dystrophy. The HOPE-3 cardiac datas American Heart Association award and physician support have bolstered bullish sentiment, while concerns about FDA scrutiny and the earlier negative advisory-panel vote on the cardiac indication keep approval uncertain.

Rocket Labs quarterly results are driving discussion: revenue and backlog growth beat expectations, but a wider-than-expected loss and Neutrons first launch being pushed to 2027 weighed on shares. Traders are split between viewing the loss as largely tied to Iridium-related costs and seeing the Neutron delay and profitability as key risks.

Ethereum is drawing attention amid a broad crypto selloff, with traders pointing to hot inflation data, increased Fed rate-hike bets, and leveraged long liquidations as sources of pressure. The discussion is largely bearish, with calls for further losses and concern about support, while some traders are buying the dip and looking for a reversal.